Clinical Trials Directory

Trials / Completed

CompletedNCT02541006

Comparison of 24 Hour Bronchodilator Efficacy of Tiotropium 18 mcg Delivered Via DISCAIR Versus SPIRIVA 18 µg Delivered Via HANDIHALER® in Patients With Moderate to Severe COPD

A Randomized, Parallel-group, Phase IV Study to Compare the Bronchodilator Efficacy of Tiotropium (18 µg Once Daily [od]) Delivered Via a DISCAIR With Tiotropium (18 µg od) Delivered Via a HandiHaler®, in Patients With Moderate-to-severe COPD

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
58 (actual)
Sponsor
Neutec Ar-Ge San ve Tic A.Ş · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The objective of this study is to compare the bronchodilator efficacy a of tiotropium inhalation via DISCAIR (18 mcg once daily) and SPIRIVA HANDIHALER® (18 mcg once daily) in patients with moderate to severe chronic obstructive pulmonary disease (COPD).

Conditions

Interventions

TypeNameDescription
DRUGTiotropium 18 mcgtiotropium 18 mcg once a day

Timeline

Start date
2014-11-01
Primary completion
2015-04-01
Completion
2015-08-01
First posted
2015-09-04
Last updated
2020-06-16

Source: ClinicalTrials.gov record NCT02541006. Inclusion in this directory is not an endorsement.

Comparison of 24 Hour Bronchodilator Efficacy of Tiotropium 18 mcg Delivered Via DISCAIR Versus SPIRIVA 18 µg Delivered (NCT02541006) · Clinical Trials Directory